Bioventus (BVS) Current Assets (2020 - 2026)

Bioventus (BVS) has reported Current Assets for 7 consecutive years, with $257.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 6.42% year-over-year to $257.5 million; the trailing twelve-month figure through Jun 2026 stood at $257.5 million (down 6.42% YoY), and the FY2025 full-year result was $272.8 million, down 1.0% from the prior year.
• Current Assets improved to $257.5 million in Q2 2026 per BVS's latest filing, from $249.8 million in the prior quarter.
• Across five years, Current Assets topped out at $308.9 million in Q2 2024 and bottomed at $245.4 million in Q2 2022.
• Historically, Current Assets has averaged $271.5 million across 5 years, with a median of $271.8 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Current Assets advanced 25.78% in 2023, then decreased 13.85% in 2024.
• Over 5 years, Current Assets stood at $272.6 million in 2022, then declined by 1.68% to $268.0 million in 2023, then gained by 2.84% to $275.6 million in 2024, then declined by 1.0% to $272.8 million in 2025, then retreated by 5.61% to $257.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $257.5 million, $249.8 million, and $272.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.